PANASONIC/AZ-BLUE-YONDER
On May 20, 2020, Panasonic Corporation announced that it is making an equity investment in Blue Yonder — the leading end-to-end supply chain software provider. The investment via a secondary sale of shares values Blue Yonder at an enterprise value of $5.5 billion. It builds upon a strong strategic relationship between the two companies, including a joint venture in Japan announced in April 2019. Panasonic will have a 20% minority ownership stake and one seat on the Board of Directors of Blue Yonder.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005307/en/
The expanded partnership between Panasonic and Blue Yonder will accelerate the promise of the Autonomous Supply Chain™. Harnessing the edge via the Internet of Things (IoT), Blue Yonder’s platform utilizes machine learning to drive faster, more context-aware business decisions — all to deliver autonomous outcomes.
Blue Yonder and Panasonic will combine resources and work closely with partner companies in Japan to fuel growth by selling Blue Yonder’s Luminate™ solutions and bringing forth new, jointly-developed solutions on the Blue Yonder Luminate Platform that enhance customers’ capabilities for supply and demand forecasting, inventory and labor optimization, and streamlining business operations.
“Modern day supply chains face a number of challenges including rapidly shifting demand, hyper-personalization of consumer needs, labor shortages and operational inefficiencies, so by further developing our relationship with supply chain software specialists Blue Yonder, I believe we will be able to make larger, more transformative contributions to a greater number of customers,” stated Yasu Higuchi, Representative Director of Panasonic Corporation and CEO of Panasonic’s Connected Solutions Company. “In order to do so, we aim to gain a deeper understanding of Blue Yonder’s advanced global solutions and business model so that we can augment and further elevate our own solutions capability. Through this collaboration, we aim to become a global leading provider of frontline process innovation.”
“I am excited about this collaboration to realize our joint vision for digital supply chain — where Blue Yonder’s platform synchronizes with Panasonic’s edge offerings to deliver more autonomous, successful business outcomes for retailers, manufacturers and logistics providers,” said Girish Rishi, CEO of Blue Yonder. “We look forward to working within our Joint Venture in Japan to deliver tremendous customer value.”
Kazuhiro Tsuga, CEO of Panasonic Corporation also commented, “I believe this investment is a vital step for the business transformation that Panasonic’s Connected Solutions Company is undertaking. Until now, the Connected Solutions Company has taken the lead in promoting corporate culture and workstyle reforms, and with this investment we are now delving into transforming our actual business model. Specifically, we will be adding the provision of software, consulting, and services to our traditional business model of selling hardware. This will allow us to support fundamental innovations in the supply chain field — many of which have been highlighted as mission-critical amidst COVID-19 disruptions — and thereby enable us to evolve our solutions to directly address our customers’ challenges. I am certain this is a bold step in the right direction.”
Blue Yonder’s global customers include many of the leading brands in manufacturing, retail and logistics, including Best Buy, BP, Caterpillar, Coca-Cola, DHL, Lowes, Mercedes Benz, PepsiCo, Procter & Gamble, Starbucks, Unilever, and Walmart. At the core of Blue Yonder’s solutions is its end-to-end Luminate Platform, which delivers seamless digital fulfillment experiences through AI-powered supply/demand planning and execution orchestration.
New Mountain Capital and funds managed by Blackstone (“Blackstone”) continue to be majority shareholders. New Mountain retains a majority of its original investment and Blackstone continues to hold its full investment in Blue Yonder. Both shareholders remain fully committed to supporting Blue Yonder’s strategic vision.
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc.
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 528 subsidiaries and 72 associated companies worldwide and reported consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic:
https://www.panasonic.com/global
About Blue Yonder
Blue Yonder (formerly JDA Software) provides seamless, friction-free commerce, empowering every organization and person on the planet to fulfill their potential. Blue Yonder’s machine learning-driven digital fulfillment platform enables clients to deliver to their customers when, how and where they want it. Applying over 35 years of domain expertise, contextual intelligence and data science, Blue Yonder is helping more than 3,300 of the world’s leading manufacturers, retailers and logistics companies create more autonomous, sustainable and profitable operations. https://blueyonder.com/
Social Networks:
Panasonic Corporation
Web: https://www.panasonic.com
Facebook: https://www.facebook.com/PanasonicCorporation
LinkedIn: https://www.linkedin.com/company/panasonic/
Twitter: https://twitter.com/panasonic
YouTube: https://www.youtube.com/user/ChannelPanasonic
Blue Yonder
Web: https://blueyonder.com/
Blog: https://blog.blueyonder.com/
Facebook: https://www.facebook.com/BlueYonderAI/
Instagram: https://www.instagram.com/blueyonder__ai/
LinkedIn: https://www.linkedin.com/company/blueyonderai
Twitter: https://twitter.com/BlueYonder
YouTube: https://www.youtube.com/c/BlueYonderAI
Source: https://news.panasonic.com/global/press/data/2020/05/en200520-2/en200520-2.html
Related Links
Connected Solutions Company, Panasonic Corporation
https://www.panasonic.com/global/corporate/cns.html
[Press Release] JDA and Panasonic to Establish Joint Venture Company in Japan (Apr 1, 2019)
https://news.panasonic.com/global/press/data/2019/04/en190401-3/en190401-3.html
Panasonic Demonstrates Unique Technology Solutions at the JDA ICON Intelligent Supply Chain Conference (May 08, 2019)
https://news.panasonic.com/global/topics/2019/67943.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005307/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom